You are here

  • Home
  • Archive
  • Volume 7, Issue 1
  • A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund’s adjuvant in melanoma patients

Article info

Article menu

Download PDFPDF

XML
Research Article
A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund’s adjuvant in melanoma patients

Authors

  • Marit M. Melssen Department of Surgery/Division of Surgical Oncology and the Human Immune Therapy Center, Cancer CenterUniversity of Virginia P.O. Box 801457 1352 Pinn Hall 22908 Charlottesville VA USA Department of Microbiology, Immunology, and Cancer BiologyUniversity of Virginia Charlottesville VA USA PubMed articlesGoogle scholar articles
  • Gina R. Petroni Department of Public Health Sciences/Division of Translational Research & Applied StatisticsUniversity of Virginia Charlottesville VA USA PubMed articlesGoogle scholar articles
  • Kimberly A. Chianese-Bullock Department of Surgery/Division of Surgical Oncology and the Human Immune Therapy Center, Cancer CenterUniversity of Virginia P.O. Box 801457 1352 Pinn Hall 22908 Charlottesville VA USA PubMed articlesGoogle scholar articles
  • Nolan A. Wages Department of Public Health Sciences/Division of Translational Research & Applied StatisticsUniversity of Virginia Charlottesville VA USA PubMed articlesGoogle scholar articles
  • William W. Grosh Department of Medicine/Division of Hematology/OncologyUniversity of Virginia Charlottesville VA USA PubMed articlesGoogle scholar articles
  • Nikole Varhegyi Department of Public Health Sciences/Division of Translational Research & Applied StatisticsUniversity of Virginia Charlottesville VA USA PubMed articlesGoogle scholar articles
  • Mark E. Smolkin Department of Public Health Sciences/Division of Translational Research & Applied StatisticsUniversity of Virginia Charlottesville VA USA PubMed articlesGoogle scholar articles
  • Kelly T. Smith Department of Surgery/Division of Surgical Oncology and the Human Immune Therapy Center, Cancer CenterUniversity of Virginia P.O. Box 801457 1352 Pinn Hall 22908 Charlottesville VA USA PubMed articlesGoogle scholar articles
  • Nadejda V. Galeassi Department of Surgery/Division of Surgical Oncology and the Human Immune Therapy Center, Cancer CenterUniversity of Virginia P.O. Box 801457 1352 Pinn Hall 22908 Charlottesville VA USA PubMed articlesGoogle scholar articles
  • Donna H. Deacon Department of Surgery/Division of Surgical Oncology and the Human Immune Therapy Center, Cancer CenterUniversity of Virginia P.O. Box 801457 1352 Pinn Hall 22908 Charlottesville VA USA PubMed articlesGoogle scholar articles
  • Elizabeth M. Gaughan Department of Medicine/Division of Hematology/OncologyUniversity of Virginia Charlottesville VA USA PubMed articlesGoogle scholar articles
  • Craig L. Slingluff Department of Surgery/Division of Surgical Oncology and the Human Immune Therapy Center, Cancer CenterUniversity of Virginia P.O. Box 801457 1352 Pinn Hall 22908 Charlottesville VA USA PubMed articlesGoogle scholar articles
  1. ↵l (434) 924-9311 cls8h{at}virginia.edu
View Full Text

Citation

Melssen MM, Petroni GR, Chianese-Bullock KA, et al
A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund’s adjuvant in melanoma patients
Journal for ImmunoTherapy of Cancer 2019;7:163. doi: 10.1186/s40425-019-0625-x

Publication history

  • Received January 18, 2019
  • Accepted May 17, 2019
  • First published June 27, 2019.
Online issue publication 
January 08, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© The Author(s). Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.